Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

AZERION Stock Bearish By 30% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of AZERION (AEX-Index: AZRN.AS) fell by a staggering 30.17% in 21 sessions from 4.74 € to 3.31 € at 01:09 EST on Thursday, after two successive sessions in a row of losses. AEX-Index is sliding 0.62% to 748.40 €, following the last session's upward trend.

About AZERION

Azerion Group N.V. operates a digital entertainment and media platform worldwide. Its integrated platform provides technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company was founded in 2014 and is headquartered in Schiphol-Rijk, the Netherlands. Azerion Group N.V. is a subsidiary of Principion Holding B.V.

Earnings Per Share

As for profitability, AZERION has a trailing twelve months EPS of -167 €.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AZERION's stock is considered to be overbought (>=80).

More news about AZERION (AZRN.AS).

Categories

stockMarket

Tags

Stock PricePrice DownMarket Session NowStock Price DownStock Market NowAZERIONAZRN.ASMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com